Startseite Kongressberichte & Archiv 24th Congress of EHA Immunotherapy in relapsed/refractory multiple myeloma

Immunotherapy in relapsed/refractory multiple myeloma

Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, et al.

RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Conclusion: Efficacy and PK co-primary endpoints were met, demonstrating non-inferiority of DARA SC to DARA IV. DARA SC had an improved safety profile with a significantly decreased IRR rate and a very short administration time. DARA SC is under investigation in ongoing phase 2 and 3 studies in MM and AL amyloidosis.

 

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, Jesus San-Miguel, et al.

A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Conclusion: Isatuximab in combination with pomalidomide and dexamethasone significantly improved PFS and ORR vs pomalidomide and dexamethasone, with a manageable safety profile. Isatuximab in combination with pomalidomide and dexamethasone is an important new treatment option for the management of RRMM.

 

Max Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, et al.

EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY

Conclusion: In this FIH study of AMG 420, a BiTE® vs BCMA, in R/R MM, there was a 70% response rate (7/10) with 5 out of 7 responders achieving a sCR at 400 µg/d, a recommended dose for further investigation.

 

Chenggong Li, Heng Mei, Yu Hu, Tao Guo, et al

IMPROVED EFFICACY AND SAFETY OF A DUAL-TARGET CAR-T CELL THERAPY TARGETING BCMA AND CD38 FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM A PHASE I STUDY

Conclusion: Our study demonstrates an improved efficacy with dual-target CAR-T therapy targeting BCMA and CD38 for RRMM with a high ORR, especially a higher rate and a longer duration of sCR. CRS and hematological toxicities are observed but manageable. Other toxicity is rare. These initial data provide strong evidence to support the further development of the dual-target CAR-T therapy for RRMM.ChiCTR1800018143

 

Chunrui Li, Jianfeng Zhou, Jue Wang, Guang Hu, et al.

CLINICAL RESPONSES AND PHARMACOKINETICS OF FULLY HUMAN BCMA TARGETING CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Conclusion:  Data from this early-stage clinical study showed the unparalleled safety and efficacy of CT103A. Major AEs were transient, manageable, and reversible. three patients who relapsed the murine BCMA CAR-T were treated with CT103A, two patients achieved CR, and one patient achieved VGPR. 100% ORR and a rapid response within 2 weeks, suggests CT103A could be developed as a competitive therapeutic to treat patients with RRMM.